Cogent Biosciences, Inc.

NasdaqGS COGT

Cogent Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -4,336.02%

Cogent Biosciences, Inc. EBT Margin is -4,336.02% for the Trailing 12 Months (TTM) ending September 30, 2024. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Cogent Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -745,775,632,067,081.50%, a -282,337,270,740,938.38% change year over year.
Cogent Biosciences, Inc. EBT Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -264.14%, a 31.91% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

NasdaqGS: COGT

Cogent Biosciences, Inc.

CEO	Mr. Andrew R. Robbins M.B.A.
IPO Date	March 29, 2018
Location	United States
Headquarters	200 Cambridge Park Drive
Employees	164
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years